Black Diamond Therapeutics, Inc.
BDTX
NASDAQ·Healthcare·Biotechnology·Mkt cap $120.3M
$2.10
▼ -1.87%
P/E
-2.84
Mkt Cap
$120.3M
52-Wk Range
$1.60–$4.94
52-Week Range
$1.60 - $4.94
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 26.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary rational drug design platform leveraging computational chemistry
- Specialized focus on non-canonical and resistant mutations with limited competition
- Brain-penetrant formulation expertise for CNS metastases and primary brain tumors
- Strategic partnership with OpenEye Scientific Software for enhanced drug discovery capabilities
Bear Case
1 risk
- Very high volatility (beta 3.3). Expect 3x market swings. Position size accordingly.
Growth
Stable outlook
Clinical trial advancement of lead programs toward regulatory milestones
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Stable
+0.5% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying BDTX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 5, 2026
Reported EPS of -$0.17 vs -$0.20 consensus (+13.0% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+13.0%
Revenue trend · last 8Q
—
—
—
—
—
—
-100%
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$70.0M
$0
$0
$0
$0
$0
Margins · last 8Q
Gross
—
Operating
—
Profit
—
Wall Street consensus
3 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Raymond James · Aug 6, 2026
vs Industry
How BDTX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related